dexamethasone and semaglutide Liraglutide mitigates dexamethasone-induced fatty acid synthase (FASN) the cluster of differentiation36 (CD36) expression: a potential treatment for glucocorticoid-induced non-alcoholic fatty liver disease (NAFLD) Semaglutide, a glucagon-like peptide-1 receptor

Zhang, N., Ping, Q., & Huang, G

This progression highlights how obesity medicine is moving toward therapies that target multiple metabolic pathways simultaneously

Just clear guidance and care designed to support your progress.

A thorough evaluation of your health and blood glucose status Assessment to determine whether Semaglutide or another therapy is most suitable Personalised diabetes care plans that include medication, nutrition counselling, and lifestyle recommendations Semaglutide is an FDA-approved GLP-1 receptor agonist used specifically for type 2 diabetes management

Accountability and support Regular coaching sessions keep you on track and motivated